Soligenix, Inc.

Equities

SNGX

US8342236044

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-18 EDT 5-day change 1st Jan Change
4.24 USD +10.99% Intraday chart for Soligenix, Inc. +25.82% -65.00%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Sector Update: Health Care Stocks Retreat Late Afternoon MT
Sector Update: Health Care Stocks Lower Thursday Afternoon MT
Soligenix Seeks Shareholders' Approval for Reverse Stock Split; Shares Fall MT
Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma CI
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa CI
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Gain Monday Afternoon MT
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation MT
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA DJ
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency CI
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board CI
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease CI
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis CI
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses CI
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Top MIdday Gainers MT
Sector Update: Health Care Stocks Advance Thursday Afternoon MT
Sector Update: Health Care MT
Soligenix Says US FDA Cleared Application for Trial of Behcet's Disease Aphthous Ulcers Treatment MT
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease CI
Soligenix Seeks Acquisitions CI
Soligenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Chart Soligenix, Inc.
More charts
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.24 USD
Average target price
40 USD
Spread / Average Target
+843.40%
Consensus
  1. Stock Market
  2. Equities
  3. SNGX Stock
  4. News Soligenix, Inc.
  5. Soligenix Seeks Shareholders' Approval for Reverse Stock Split; Shares Fall